The clinical significance of RASSF1A and CDH1 hypermethylation in breast cancer patients

Kajal Nandi; Prasant Yadav; Rashid Mir; Nita Khurana; P.N.Agarwal; Alpana Saxena

Volume : VII, Issue : I, January - 2018

The clinical significance of RASSF1A and CDH1 hypermethylation in breast cancer patients

Kajal Nandi, Prasant Yadav, Rashid Mir, Nita Khurana, P. N. Agarwal, Alpana Saxena

Abstract :

Introduction: Aberrant DNA methylation patterns in serum DNA might be used as a biomarker for the early diagnosis and management of cancer patients. The aim of present study was to evaluate DNA methylation of RASSF1A and CDH1 in circulating cell free DNA (cfDNA) from serum and paired tissue DNA samples of east cancer patients.

Material and methods: Methylation‑specific PCR was used to assess the methylation status of the two genes in serum and paired tissue sample DNA of 50 east cancer patients. Biochemical parameters were assessed using an electrochemiluminescence analyzer.

Results: Significant correlation found between methylation status of RASSF1A and CDH1 in serum and paired tissue samples of patients. Among clinicopathological findings, CDH1 methylation showed significant association with advance staging and tumor and methylation of RASSF1A exhibited significant association with progesterone receptor and estrogen receptor status in both serum and paired tissue. Vitamins levels were significantly high in cases compared to control group. High folic acid levels were significantly associated with the RASSF1A methylation.

Conclusions: These findings suggest that methylation of cfDNA may be important in the early detection of east cancer.